CLS (CHARTER LIFE SCIENCES) is an early stage life sciences venture capital investor.

CLS makes initial portfolio company investments in life sciences companies that are seeking capital to obtain initial proof-of-efficacy of their products (see Investment Criteria), and we continue to support our successful portfolio companies with follow on investments until they are acquired or go public.

Our team is led by four Managing Partners who have worked together to create and build life sciences companies for over twenty years. Our team brings extensive scientific, clinical, regulatory, operational and finance experience to each of our portfolio companies.

We play an active role in helping entrepreneurs build successful companies. Our time, energy and passion is devoted to building early stage life sciences opportunities. As a result, your company will be compared only against other early stage opportunities. So, at CLS, your early stage biotech medical device or health care information technology company will not be compared against a PIPE investment in an undervalued Phase III company, as an example. Early stage is what we do, and all we do.


We understand that early stage companies do not have all the answers and do not have all the data. We understand that many basic questions need investment capital to answer, and we understand that development plans and milestones are subject to lots of uncertainty and change. We understand what it takes to build a management team from scratch, and we invest in companies with little or no existing management. In short, we understand what it is to be an early stage entrepreneur, because each of us has been one.

Please look carefully at our investment criteria and our team, and if we are the type of partner that you would like to work with, please contact us.

In the News

KFx Medical, LLC announced that it has entered into a license agreement with Wright Medical Technology, Inc. (NASDAQ:WMGI) relating to KFx patents used in knotless double row rotator cuff repair. Under the agreement, Wright and its affiliates will have the right to promote the use of products and techniques for knotless double row rotator cuff repair as claimed in US Patent number 7,585,311 and related patents and applications for the life of those patents. In addition, KFx and Wright agreed to dismiss the related pending litigation between the parties. Arthrex, Inc. has paid in excess of $35m in damages and [more]
Weight Loss Data Presented At Annual Obesity Week 2017 Conference ReShape Lifesciences Inc. (NASDAQ:RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, today announced new data that was presented this week at the ObesityWeek 2017 conference in Washington D.C. "Obesity has become a global epidemic that involves significant health issues, comorbidities, and high associated costs to the healthcare system," said Dan Gladney, President, Chief Executive Officer and Chairman of the Board of ReShape Lifesciences. "New, minimally invasive treatment options that are anatomy friendly and help patients manage their disease are required, as existing options are [more]